IBM’s Watson Supercomputer: A Revolutionary Advance in Cancer Genomics

In 2003, a young medical student named Lukas Wartman was navigating the challenging landscape of a fourth-year program at Washington University in St. Louis. He was contemplating a future in oncology, but fate had a cruel twist in store. Wartman himself received a diagnosis of acute lymphoblastic leukemia, a cancer affecting the blood and bone marrow. The diagnosis was daunting. This leukemia, usually treatable in children, often proves fatal for adults.

Wartman underwent an exhaustive two years of chemotherapy, which resulted in a fleeting remission. He managed to complete his medical studies, but by 2008 the leukemia relapsed.

During this challenging time, The Genome Institute approached Wartman about participating in an innovative research study. The goal was comprehensive sequencing of his personal genome. The results were astonishing. Analysis of Wartman’s RNA revealed an overabundance of a gene known as FLT3. Upon this discovery, it was determined that Sutent, a drug typically used to treat kidney cancer, was Wartman’s best hope. The drug targets the FLT3 gene, leading Wartman into remission for a third time. He is currently cancer-free, owing his life to the ground-breaking strides in genomics.

IBM Watson, a ground-breaking AI developed by IBM, recently announced a partnership with 14 leading cancer institutes to further advance genomics research. Wartman, who now serves as the Assistant Director of Cancer Genomics at Washington University’s McDonnell Genome Institute, had the honor of announcing this partnership at the inaugural World of Watson event in Brooklyn.

The Watson AI made waves in the tech world by participating in various sectors ranging from education to culinary arts. Watson’s foray into genomics marks a significant leap in leveraging big data to simplify complex processes like personalized cancer diagnoses.

According to IBM, one patient’s genome equals approximately 100 gigabytes of data. Such vast quantities of information would be near impossible for a human to sift through, but Watson can handle it. IBM executives envision Watson as the cornerstone of the Watson Health initiative.

As Wartman optimistically shared, using vast amounts of data in a HIPAA-compliant way to gain insights into the myriad ways cancer materializes in individuals is game-changing. But he also emphasized that while AI technologies like Watson are impressive, they are complementary to the doctor-patient relationship, not a replacement.

Watson’s strength lies in its capacity to understand a patient’s genetic code. This detailed genetic insight can allow doctors to locate bespoke treatment options based on the unique genetic markers in each patient, just as Sutent was for Wartman.

When Wartman began his cancer journey 12 years ago, he noted that the treatment protocol hadn’t changed drastically from the previous decades. With Watson’s advent, the turnaround time in interpreting results has significantly improved. The goal of these advancements is to make genetic data more accessible for everyone, not just in large medical institutions.

As Wartman aptly summarizes, “This sequencing technology — using these analytic platforms — gives us a better opportunity to make headway against cancer than ever before.” Technology like IBM’s Watson doesn’t just fight against cancer; it enables us to enter into an era where we can win the war against this devastating disease.

*This article was updated in 2025 to reflect modern realities.*